---
title: 'Baseline monocyte count predicts symptom improvement during intravenous ketamine
  therapy in treatment-resistant depression: a single-arm open-label observational
  study'
date: '2024-07-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39045550/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240724183054&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Our prospective single-arm open-label observational study
  demonstrated that baseline AMC reliably predicted symptom improvement during intravenous
  ketamine treatment in TRD patients. AMC could therefore serve as a simple and easily
  accessible marker for symptom improvement during ketamine therapy in daily clinical
  practice. Future studies with larger sample sizes and a more detailed longitudinal
  assessment of AMC subtypes are needed to better understand the specific ...'
disable_comments: true
---
CONCLUSIONS: Our prospective single-arm open-label observational study demonstrated that baseline AMC reliably predicted symptom improvement during intravenous ketamine treatment in TRD patients. AMC could therefore serve as a simple and easily accessible marker for symptom improvement during ketamine therapy in daily clinical practice. Future studies with larger sample sizes and a more detailed longitudinal assessment of AMC subtypes are needed to better understand the specific ...